AF
VERV

Amalgamated Financial’s Verve Therapeutics VERV Stock Holding History

Amalgamated Financial’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$100K Buy
+4,398
New +$126K ﹤0.01% 2148

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Amalgamated Financial's VERV Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Verve Therapeutics (VERV) in Q1 2022: 4,398 shares worth $100K. The stake represents ﹤0.01% of the portfolio and ranks #2148 among its holdings.

92 funds tracked by Wall St. Rank hold VERV as of Q1 2022.

  • Amalgamated Financial held 4,398 shares of Verve Therapeutics worth $100K as of Q1 2022.
  • Verve Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Verve Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2148 holding.
  • 92 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.